TearSolutions specializes in innovative therapies for ocular surface diseases. The company has pioneered LacripepTM, a groundbreaking peptide therapy aimed at enhancing tear film quality, thereby addressing critical issues related to corneal health and patient comfort in the field of pharmaceuticals and biotechnology.
Ōsaka, • Japan
Tokyo, • Japan
Massachusetts, • United States
Quebec, • Canada • Pharmaceuticals
Synthetic neurotrophin mimetics, Ocular surface disease therapies, Dry eye disease treatment, Advanced clinical development, Innovative ophthalmic therapies
Texas, • United States
Massachusetts, • United States
California, • United States
New Jersey, • United States